(MLAB) Mesa Laboratories - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US59064R1095

MLAB: Life Sciences Tools, Quality Control Products, Laboratory Services

Mesa Laboratories, Inc. is a leading developer, manufacturer, and provider of life sciences tools and quality control products. With a strong presence in North America, Europe, the Asia Pacific, and other international markets, the company serves a diverse range of industries, including pharmaceuticals, medical devices, and healthcare. Mesa Labs is known for its comprehensive portfolio of products and services designed to enhance quality control and efficiency in various scientific applications.

The company operates through four primary business segments, each catering to distinct needs within the life sciences and quality control sectors. The Sterilization and Disinfection Control segment specializes in biological, chemical, and cleaning indicators. These products are crucial for assessing the effectiveness of sterilization and decontamination processes in healthcare and pharmaceutical settings. Additionally, this segment offers specialized testing and laboratory services tailored to the dental and pharmaceutical industries, ensuring compliance with stringent regulatory standards.

The Clinical Genomics segment focuses on genetic analysis, offering the MassARRAY system, a state-of-the-art tool for DNA sample analysis. This system, along with its consumables such as chips, panels, and reagent solutions, is widely used in clinical laboratories for testing inherited genetic diseases, pharmacogenetics, oncology, infectious diseases, and toxicology. The versatility of the MassARRAY system also extends to research applications, making it a valuable asset in advancing genetic understanding and personalized medicine.

The Biopharmaceutical Development segment is dedicated to providing innovative solutions for protein analysis and peptide synthesis. The product line includes Gyrolab xPand

Additional Sources for MLAB Stock

MLAB Stock Overview

Market Cap in USD 614m
Sector Technology
Industry Scientific & Technical Instruments
GiC Sub-Industry Life Sciences Tools & Services
IPO / Inception 1995-01-25

MLAB Stock Ratings

Growth Rating -41.8
Fundamental 1.74
Dividend Rating 32.3
Rel. Strength 14.7
Analysts 3.5/5
Fair Price Momentum 97.18 USD
Fair Price DCF 113.44 USD

MLAB Dividends

Dividend Yield 12m 0.67%
Yield on Cost 5y 0.34%
Annual Growth 5y 0.00%
Payout Consistency 96.2%

MLAB Growth Ratios

Growth Correlation 3m -87.3%
Growth Correlation 12m 52.3%
Growth Correlation 5y -81.9%
CAGR 5y -13.21%
CAGR/Max DD 5y -0.18
Sharpe Ratio 12m 0.27
Alpha 1.60
Beta 1.405
Volatility 56.03%
Current Volume 32.3k
Average Volume 20d 58.1k
What is the price of MLAB stocks?
As of April 26, 2025, the stock is trading at USD 116.48 with a total of 32,276 shares traded.
Over the past week, the price has changed by +6.84%, over one month by -7.13%, over three months by -16.40% and over the past year by +15.01%.
Is Mesa Laboratories a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Mesa Laboratories is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 1.74 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MLAB as of April 2025 is 97.18. This means that MLAB is currently overvalued and has a potential downside of -16.57%.
Is MLAB a buy, sell or hold?
Mesa Laboratories has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold MLAB.
  • Strong Buy: 2
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • Strong Sell: 1
What are the forecast for MLAB stock price target?
According to ValueRays Forecast Model, MLAB Mesa Laboratories will be worth about 109.1 in April 2026. The stock is currently trading at 116.48. This means that the stock has a potential downside of -6.37%.
Issuer Forecast Upside
Wallstreet Target Price 141.7 21.6%
Analysts Target Price 141.7 21.6%
ValueRay Target Price 109.1 -6.4%